Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1
β Scribed by Cox, Lynne S.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 91 KB
- Volume
- 183
- Category
- Article
- ISSN
- 0022-3417
No coin nor oath required. For personal study only.
β¦ Synopsis
Many tumour therapies act by inducing a cellular damage response pathway mediated by the tumour suppressor protein p53. Alternative outcomes of p53 induction include apoptosis or transient cell-cycle arrest, both thought to require the transcriptional activity of wild-type p53. Current research highlights the action of a p53-activated gene, p21 Cip1/WAF1/Sdi1 , which encodes a cyclin-kinase inhibitor important in mediating p53-dependent cell-cycle arrest, while programmed cell death in response to DNA damage requires transcriptionally active p53 but not activation of p21 Cip1/WAF1/Sdi1 . This review examines the roles of p53 and p21 Cip1/WAF1/Sdi1 in controlling cell proliferation, in the light of a new study on expression of p53 and p21 Cip1/WAF1/Sdi1 in squamous cell carcinoma of the larynx. 1997 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
the pancreas were immunostained for p53 and p21. Nuclear expression was scored as absent, focal (Γ΅10%), moderate (10 -50%), or strong or diffuse
Codon 273 is one of the hot spots of missense mutation of the p53 tumor suppressor gene found in human cancers. We have previously reported that a mutation at codon 273, p53-273L (Arg 3 Leu), suppresses cell growth despite its having no p53-specific transactivation activity. To further elucidate the
p21 WAF1/CIP1 is a downstream mediator of p53 and mediates growth arrest by inhibiting the action of G 1 cyclin-dependent kinases. Since cellular differentiation is frequently characterized by G 1 arrest, we examined whether p21 WAF1/CIP1 overexpression would induce growth suppression and differenti
BACKGROUND. The clinical course of laryngeal squamous cell carcinoma (LSCC) varies considerably among patients. New biologic markers are needed to facilitate the stratification of individual patients within the conventional clinicopathologic stages of LSCC. METHODS. Eighty-three LSCCs from an equal
p21 WAF1/Cip1 is an inhibitor of cdk/cyclin complexes, and thus regulates the cell cycle. p21 is also related to cell differentiation and is regulated by wild-type p53, although p53-independent regulatory pathways have been proposed. In order to analyse p21 expression as well as its relationship wit